A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-56136379
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Bersacapavir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
Most Recent Events
- 19 Apr 2021 Status changed from recruiting to completed.
- 16 Feb 2021 Planned End Date changed from 9 Mar 2021 to 7 Apr 2021.
- 19 Jan 2021 Planned primary completion date changed from 17 Dec 2020 to 9 Mar 2021.